Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction

A composition comprising:

• a modulator of a mutant CFTR protein adapted for use in the manufacture of a medication for the treatment of diseases associated with CFTR protein malfunction including:
• a compound of general formula (I)
• its tautomers, E and Z geometrical isomers, optically active forms such as enantiomers, diastereomers and their racemate forms or a mixture of stereoisomeric forms or its pharmaceutically acceptable salts thereof or complexes thereof;
• wherein Z1 is independently selected from the group consisting of:
• —CnH(2n)—, which is branched or unbranched wherein n is an integer from 1 to 5;
• —CnH(2n−2)— in E or Z geometrical conformation which is branched or unbranched wherein n is an integer from 2 to 5;
• —CnH(2n−4)— which is branched or unbranched wherein n is an integer from 2 to 5;
• —CR′H—, —C2H3R′—, E or Z—C2HR′—, —C3H5R′—, E or Z—C3H3R′—, —OCH2—, —CH2O—, —NR″CH2—, —CH2NR″—;
• wherein R′ is independently selected from the group consisting of:
• —H, halogen, —NH2, —OH, —CN, CF3, —CHF2, —CH2F, —SH, —SCN, —CH3, —C2H5;
• wherein R″ is independently selected from the group consisting of:
• —H, —CH3, —C2H5;
• wherein R1 and R2 are independently selected from the group consisting of aromatic ring or heteroaromatic ring.